AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency.[ Read More ]
The intrinsic value of one ANGO stock under the base case scenario is HIDDEN Compared to the current market price of 6.81 USD, AngioDynamics, Inc. is HIDDEN
Current Assets | 193 M |
Cash & Short-Term Investments | 76.1 M |
Receivables | 43.6 M |
Other Current Assets | 73.6 M |
Non-Current Assets | 124 M |
Long-Term Investments | 0 |
PP&E | 41.5 M |
Other Non-Current Assets | 82.9 M |
Current Liabilities | 91.2 M |
Accounts Payable | 37.8 M |
Short-Term Debt | 1.98 M |
Other Current Liabilities | 51.4 M |
Non-Current Liabilities | 20.9 M |
Long-Term Debt | 3.94 M |
Other Non-Current Liabilities | 17 M |
Revenue | 304 M |
Cost Of Revenue | 149 M |
Gross Profit | 155 M |
Operating Expenses | 252 M |
Operating Income | -97.7 M |
Other Expenses | 86.6 M |
Net Income | -184 M |
Net Income | -184 M |
Depreciation & Amortization | 27.7 M |
Capital Expenditures | -5.77 M |
Stock-Based Compensation | 10.5 M |
Change in Working Capital | 14.4 M |
Others | 99.9 M |
Free Cash Flow | -33.9 M |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
1 month ago
Oct 10, 2024
|
Bought 608 USD
|
Nighan Warren JR
SVP Quality and Regulatory |
+ 100
|
6.08 USD |
1 month ago
Oct 07, 2024
|
Bought 4.68 K USD
|
Nighan Warren JR
SVP Quality and Regulatory |
+ 768
|
6.09 USD |
1 month ago
Oct 08, 2024
|
Bought 9.96 K USD
|
Trowbridge Stephen A
EVP and CFO |
+ 1700
|
5.86 USD |
1 month ago
Oct 07, 2024
|
Bought 121 K USD
|
Clemmer James C
President and CEO |
+ 20000
|
6.03 USD |
7 months ago
Apr 08, 2024
|
Bought 67 K USD
|
Clemmer James C
President and CEO |
+ 10000
|
6.7 USD |
1 year ago
Jan 31, 2023
|
Sell 60 K USD
|
Helsel Dave
SVP Global Operations and R&D |
- 4633
|
12.95 USD |
2 years ago
Oct 12, 2022
|
Bought 15 K USD
|
Trowbridge Stephen A
EVP and CFO |
+ 1083
|
13.82 USD |
2 years ago
Oct 10, 2022
|
Bought 150 K USD
|
Clemmer James C
President and CEO |
+ 10000
|
15 USD |
2 years ago
Jul 29, 2022
|
Sell 112 K USD
|
Helsel Dave
SVP Global Operations and R&D |
- 5000
|
22.44 USD |
2 years ago
Apr 28, 2022
|
Sell 78.8 K USD
|
Helsel Dave
SVP Global Operations and R&D |
- 3513
|
22.44 USD |
2 years ago
Apr 11, 2022
|
Sell 143 K USD
|
JOHNSON WESLEY
Director |
- 6201
|
23 USD |
2 years ago
Apr 11, 2022
|
Sell 30.2 K USD
|
JOHNSON WESLEY
director: |
- 1299
|
23.26 USD |
2 years ago
Jan 12, 2022
|
Bought 22.6 K USD
|
Trowbridge Stephen A
EVP and CFO |
+ 1000
|
22.64 USD |
2 years ago
Jan 11, 2022
|
Bought 228 K USD
|
Clemmer James C
President and CEO |
+ 10000
|
22.84 USD |
3 years ago
Oct 20, 2021
|
Sell 97.7 K USD
|
Helsel Dave
SVP Global Operations and R&D |
- 3494
|
27.97 USD |
3 years ago
Oct 15, 2021
|
Sell 335 K USD
|
Centea Scott
Sr. VP/GM, Global VIT |
- 12000
|
27.92 USD |
3 years ago
Oct 05, 2021
|
Sell 292 K USD
|
Campbell Chad Thomas
SVP/GM, Vascular Access |
- 10748
|
27.15 USD |
3 years ago
Apr 14, 2021
|
Sell 83.8 K USD
|
Helsel Dave
SVP Global Operations and R&D |
- 3500
|
23.93 USD |
3 years ago
Jan 20, 2021
|
Sell 120 K USD
|
JOHNSON WESLEY
Director |
- 6500
|
18.53 USD |
4 years ago
Aug 11, 2020
|
Bought 9.5 K USD
|
Trowbridge Stephen A
EVP and CFO |
+ 1013
|
9.38 USD |
4 years ago
Jul 31, 2020
|
Bought 330 K USD
|
Clemmer James C
President and CEO |
+ 40000
|
8.26 USD |
5 years ago
Oct 25, 2019
|
Bought 213 K USD
|
Clemmer James C
President and CEO |
+ 15000
|
14.19 USD |
5 years ago
Jul 16, 2019
|
Sell 293 K USD
|
Gould Kevin J
Director |
- 13650
|
21.45 USD |
6 years ago
Nov 07, 2018
|
Sell 41.7 K USD
|
Greiner Michael
EVP and CFO |
- 1939
|
21.53 USD |
7 years ago
Nov 15, 2017
|
Sell 446 K USD
|
Richard Stark
SVP, GM - Oncology |
- 27409
|
16.29 USD |
7 years ago
Jul 24, 2017
|
Bought 5.06 K USD
|
REED JAN STERN
Director |
+ 316
|
16 USD |
7 years ago
Jul 21, 2017
|
Bought 78.6 K USD
|
DONNELLY HOWARD W
Director |
+ 5000
|
15.72 USD |
7 years ago
Jul 21, 2017
|
Bought 79 K USD
|
Clemmer James C
President and CEO |
+ 5000
|
15.79 USD |
7 years ago
Jul 20, 2017
|
Bought 313 K USD
|
Clemmer James C
President and CEO |
+ 20000
|
15.64 USD |